**Supplementary Table 2. Sensitivity analysis for the impact on OCT on tumor characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **No OCT****n=450****(%)** | **OCT total n=103****(%)** | **OCT only1****n=67****(%)** |  |
| 88 (20)258 (57)104 (23) | 31 (30)45 (44)27 (26) | 21 (31)25 (38)21 (31) | **T≤1 cm** **1<T≤2** **T>2 cm** |
| 79 (18) | 16 (16) | 10 (15) | **Node positive** |
| 354 (79)62 (14)34 (7) | 89 (86)9 (9)5 (5) | 56 (84)7 (10)4 (6) | **IDC** **ILC** **Other**  |
| 64 (18)231 (63)70 (19) | 16 (18)66 (72)9 (10) | 12 (21)41 (72)4 (7) | **Grade** **1** **2****3** |
| 8 (2)97 (21)345 (77) | 3 (3)23 (22)77 (75) | 3 (5)15 (22)49 (73) | **ER intensity****Weak****Moderate****Strong** |
| 64 (14) | 8 (8) | 5 (8) | **PR Negative**  |
| 22 (5) | 2 (2) | 2 (3) | **PNI present** |
| 21 (5) | 21 (5) | 8 (12) | **LVI present** |
| 72 (16) | 13 (18) | 5 (8) | **Ki67 >20%** |
| 83 (18) | 16 (16) | 9 (13) | **Oncotype RS>25** |

1 OCT only- included women who used OCT and were not treated with hormonal replacement therapy or fertility treatment

Abbreviation: OCT= Oral contraceptive therapy, , T=Tumor size, IDC= Invasive ductal carcinoma, ILC= Invasive lobular carcinoma, ER=Estrogen receptor, PR= Progesterone receptor, PNI= Perineural invasion, LVI= Lymphovascular invasion, RS= Recurrence score.